non-viral hepatitis Flashcards

1
Q

what is NAFLD ?

A

non-alcoholic fatty liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the requirements for defining NAFLD ?

A
  • evidence of hepatic steatosis either by imaging or histology
    along with lack of secondary causes of hepatic fat accumulation

- lack of secondary cause of hepatic fat accumulation such as significant alcohol consumption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is defined as significant alcohol consumption ?

A

> 21 drinks for men per week

>14 drinks for women per week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the difference between NASH and NAFLD ?

A

NASH - non alcoholic steato-hepatitis where there is inflammation around the fatty tissue
NAFLD - no inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the commonly associated abnormalities with NASH?

A
insulin resistance 
metabolic syndrome 
T2DM 
obesity 
dyslipidemia 
hypertension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is metabolic syndrome ?

A
it is defined as having at least two of the following:
obesity 
Insulin resistance 
dyslipidemia 
hypertension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how does insulin resistance result in the accumulation of triglycerides in hepatocytes ?

A

impaired oxidation of fatty acids
increased synthesis and uptake of fatty acids
decreased hepatic secretion of LDL cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what happens to fat laden hepatocytes ?

A

they become exposed to free oxygen radicals which causes oxidative stress
causes mitochondrial death
and eventually cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the presentation of NAFLD like ?

A

usually asymptomatic but may present with vague right upper quadrant pain with elevated transaminases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what may appear upon ultrasound in NAFLD?

A

bright liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the management of NAFLD ?

A

most importantly lifestyle modification

weight loss reduces hepatic steatosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what medical treatment can be taken for cases of NASH ?

A

Pioglitazone ( improves histology of the patient)

Vitamin E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what surgical treatment may be considered for NAFLD ?

A

bariatric surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are medications that are not recommended for the treatment of NASH ?

A

Metformin
GLp-1 agonists
Omega 3 fatty acids ( non specific for NASH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are the treatment options for advanced cases of NASH and NAFLD ?

A

liver transplantation

patients with cirrhosis should be screened for HCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the pathogenesis of primary biliary cholangitis ?

A

chronic inflammatory autoimmune, more common in smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

if primary biliary cholangitis is left untreated what is the outcome ?

A

end stage biliary cirrhosis

18
Q

what is PBC characterized by ?

A

destruction of intrahepatic bile ducts
portal inflammation
scarring

19
Q

what are the cardinal features of PBC ?

A

non-suppurative destruction of small and medium sized intrahepatic bile ducts

20
Q

what is the onset of PBC ?

A

insidious onset

21
Q

what cann be found in serology in PBC ?

A

AMA positive

22
Q

what are the AMA directed against ?

A

pyruvate dehydrogenase complex

23
Q

what genetic association is there with PBC ?

A

HLA-DR8

24
Q

what is the clinical picture of PBC ?

A
fatigue 
pruritus may precede by jaundice 
scratch marks 
right upper quadrant abdominal discomfort 
jaundice 
bone pain or fractures 
xanthelasma 
mild hepatomegaly 
splenomegaly with the development of portal hypertension
25
Q

what diseases are associated with PBC?

A
Autoimmune hashimotos thyroiditis 
Sjogren's disease 
Celiac disease 
Systemic sclerosis 
IBD
26
Q

what is the pattern of cholestasis in lab results ?

A

raised ALP
raised GGT
hyperbilirubinemia

27
Q

when do we consider the cholestasis chronic ?

A

when it lasts over 6 months

28
Q

what other extrahepatic causes can raise ALP?

A

Rapid bone growth in children
Pagets disease
vitamin D deficiency
Pregnancy

29
Q

what is the first step in diagnosing PBC ?

A

abdominal ultrasound to exclude any mechanical obstruction of the bile duct
if there is any uncertainty then a liver biopsy may be needed

30
Q

what is the management for PBC?

A

oral UDCA at 13-15 mg/kg/day

31
Q

what can be given for the pruritus ?

A

cholestyramine

32
Q

how can we asses osteoporosis inn nPBC patients ?

A

DEXA scan n

33
Q

what is primary sclerosing cholangitis ?

A

chronic cholestatic disorder characterized by progressive fibrosis and destruction of extra hepatic and intrahepatic bile ducts of all sizes

34
Q

what is the diagnostic criteria for PSC?

A

beading and stenosis of the biliary system on cholangiography
absence of history of bile duct surgery
exclusion of bile duct cancer

and is a diagnosis of exclusion

35
Q

what is the clinical picture of PSC?

A

fatigue
intermittent jaundice
right upper quadrant abdominal pain
pruritus

36
Q

what diseases are associated with PSC ?

A

Ulcerative colitis

37
Q

what is the most common cause of death in PSC patients ?

A

cholangiocarcinoma

38
Q

what does the biochemical screening show in PSC?

A

cholestatic pattern

39
Q

what is the gold standard investigation inn PSC ?

A

MRCP

40
Q

when can we use ERCP in PSC ?

A

for therapeutic purposes inn the case of obstruction of a large duct

41
Q

what is the treatment for PSC?

A

cholestryamine may be used for the pruritus
endoscopic therapy
| ERCP

42
Q

what is the best predictor of severe fibrosis and disease progression in patients with metabolic syndrome ?

A

presence of T2DDM
obesity